Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]

Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]

Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks cholesterol absorption. Both elevate serum PCS...

Full description

Bibliographic Details
Main Authors: Brandon Ason, Samnang Tep, Jr. Harry R. Davis, Yiming Xu, Glen Tetzloff, Beverly Galinski, Ferdie Soriano, Natalya Dubinina, Lei Zhu, Alice Stefanni, Kenny K. Wong, Marija Tadin-Strapps, Steven R. Bartz, Brian Hubbard, Mollie Ranalletta, Alan B. Sachs, W. Michael Flanagan, Alison Strack, Nelly A. Kuklin
Format: Article
Language:English
Published: Elsevier 2011-04-01
Series:Journal of Lipid Research
Subjects:
cholesterol/metabolism
drug therapy
gene expression
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520409022

Internet

http://www.sciencedirect.com/science/article/pii/S0022227520409022

Similar Items